ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts

Roche has rolled out new data showing mosunetuzumab can trigger complete responses in a tough group—lymphoma patients failed by CAR-Ts and other drugs. The phase 1/2b linked the bispecific antibody to long-lasting responses in a significant minority of hard-to-treat non-Hodgkin lymphoma patients.